Dr. Chao Liang obtained Ph.D. degree from Hong Kong Baptist University in 2016. After graduation, he worked as Post-doctoral Research Fellow and Research Assistant Professor in Hong Kong Baptist University. Since 2020, Dr. Chao Liang was employed as Associate Professor in Department of Biology, Southern University of Science and Technology. Dr. Chao Liang focuses on mechanistic studies, translational medicine and precision medicine in bone & joint diseases and tumors.

Research Interests：

◆ Mechanistic studies in bone & joint diseases and tumors

◆ Translational medicine in bone & joint diseases and tumors

◆ Precision medicine in bone & joint diseases and tumors

Professional Experience：

◆ 2018-2020, Research Assistant Professor, Hong Kong Baptist University

◆ 2016-2018, Post-doctoral Research Fellow, Hong Kong Baptist University

Educational Background：

◆ 2013-2016, Ph.D., Hong Kong Baptist University, Hong Kong SAR, China

◆ 2010-2013, M.Sc. Anhui Medical University & Academy of Military Medical Science, China

◆ 2006-2010, B.Sc. Taishan Medical University, Shandong, China

Honors & Awards：

◆ 2014 ASBMR Young Investigator Award

Selected Publication：

1. Liang C*, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DW, Pan X, Zhang BT, Lu C, Zhang H, Yue K, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu A, Zhang G. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med.2015 Mar;21(3):288-94. doi: 10.1038/nm.3791.

2. Liang C*, Peng S, Li J, Lu J, Guan D, Jiang F, Lu C, Li F, He X, Zhu H, Au DWT, Yang D, Zhang BT, Lu A, Zhang G. Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat Commun. 2018 Aug 24;9(1):3428. doi: 10.1038/s41467-018-05974-z.

3. Liang C*#, Li J, Lu C, Xie D, Liu J, Zhong C, Wu X, Dai R, Zhang H, Guan D, Guo B, He B, Li F, He X, Zhang W, Zhang BT, Zhang G, Lu A. HIF1α inhibitionfacilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nat Commun. 2019 Oct 8;10(1):4579. doi: 10.1038/s41467-019-12163-z.

4. Liang C*#, Li F, Wang L, Zhang ZK, Wang C, He B, Li J, Chen Z, Shaikh AB, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au DWT, Lu C, Zhu H, Zhang BT, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials. 2017 Sep 13;147:68-85. doi: 10.1016/j.biomaterials.2017.09.015.

Li F, Lu J, Liu J, Liang C*, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang BT, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017 Nov 9;8(1):1390. doi: 10.1038/s41467-017-01565-6.